<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02157974</url>
  </required_header>
  <id_info>
    <org_study_id>14-0542</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02157974</nct_id>
  </id_info>
  <brief_title>Liver and Fat Regulation in Overweight Adolescent Girls</brief_title>
  <acronym>APPLE</acronym>
  <official_title>Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women with polycystic ovarian syndrome (PCOS) have increased rates of hepatic steatosis
      compared to weight similar women with regular menses. It is unclear if this is related to
      high testosterone or insulin resistance. The investigators will assess hepatic glucose
      release, rates of lipolysis and hepatic de novo lipogenesis in the fasted and postprandial
      state to determine if alterations in the processes contribute to hepatic steatosis.
      Participants will be overweight, sedentary girls with or without PCOS. Those with PCOS will
      either be medication naive, or must be taking metformin or combined oral contraceptives
      (COCPs) for a period of at least 6 months prior to study procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic glucose release will be assessed with a stable isotope glycerol tracer, lipolysis
      with a glycerol tracer, and hepatic de novo lipogenesis with an acetate tracer. Data will be
      collected fasting and after a glucose challenge. The degree of hepatic steatosis and
      abdominal fat partitioning will be assessed with Magnetic Resonance Imaging (MRI), and total
      body composition with Dual-energy X-ray absorptiometry (DEXA).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hepatic glucose release</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Hepatic glucose release will be measured by the rate of appearance of a glucose tracer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic phosphate concentrations</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Hepatic phosphate relative concentrations will be measured with 31 phosphorus magnetic resonance spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of lipolysis</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Rate of lipolysis will be measured by the rate of appearance of a glycerol tracer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic steatosis</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Determination of liver fat content via MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic de novo lipogenesis</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Hepatic de novo lipogenesis will be measured by with an acetate tracer.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Whole Body Insulin Sensitivity</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Participants will undergo a 75 gram oral glucose tolerance test, and whole body insulin sensitivity will be expressed as Si, calculated via the oral minimal model.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Apnea Hypopnea Index (AHI) will be measured using WatchPAT. In children and adolescents the scale that will be used is AHI&gt;5 is considered mild sleep apnea. The higher the AHI, indicates more severe sleep apnea.</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleep duration</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Sleep duration will be assessed using home actigraphy</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiome</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Stool microbiome profiling</description>
  </other_outcome>
  <other_outcome>
    <measure>Amino Acid Metabolomics: glutamate</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Targeted amino acid metabolomics will be performed to measure glutamate</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid Metabolomics: 16n1</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Targeted lipid metabolomics will be performed to measure 16n1</description>
  </other_outcome>
  <other_outcome>
    <measure>Bile Acid Metabolomics: sphingosine-1-phospate</measure>
    <time_frame>Within 4 months from Screening Visit</time_frame>
    <description>Targeted bile acid metabolomics will be performed to measure sphingosine-1-phospate</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Hepatic Steatosis</condition>
  <condition>Polycystic Ovarian Syndrome</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>PCOS, medication naive + Byetta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Up to 25 girls without PCOS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCOS medication naive</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCOS on COCPs</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCOS on metformin</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta 5Mcg Pen Injection</intervention_name>
    <description>10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola</description>
    <arm_group_label>PCOS, medication naive + Byetta</arm_group_label>
    <other_name>Exenatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females

          -  2 years post-menarche

          -  BMI percentile &gt;90%

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Anemia

          -  Liver disease

          -  Medications known to effect insulin sensitivity

          -  Cause of oligomenorrhea or hirsutism other than PCOS,

          -  &gt;3 hours a week of moderate exercise.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Cree Green, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Anshutz Medical Campus/Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2014</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will only be shared with IRB approved personnel.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

